ClinicalTrials.gov
public full text
Public Domain
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Acute Promyelocytic Leukemia 2006 (APL)#1353029
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL#1029994
- Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL#917068
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC#825406
- Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia#1320286
Record · ID 1372657
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive